ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 803

Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis

Helin Masyan, Sinem Nihal Esatoglu, Ayse Merve Celik, Vedat Hamuryudan, Hasan Yazici and Emire Seyahi, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Cardiovascular disease, comorbidity and rheumatic disease, Takayasu.s arteritis

Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In addition to the occlusive vasculitis, hypertension and accelerated atherosclerosis are probably risk factors of the cardiovascular complications in Takayasu arteritis (TA). Although, management of traditional cardiovascular risk factors is recommended to diminish these cardiovascular complications, we still do not know whether traditional risk factors and other comorbid conditions are increased or operative. We looked at the frequency of traditional atherosclerotic risk factors and comorbid conditions among pts with TA.

Methods: Between March and December 2016, we studied consecutive 88 TA pts and 81 systemic lupus erythematosus (SLE) pts. In addition, 111 hospital workers were studied as healthy controls. Participants were interviewed with the help of a standardized questionnaire that assesses the presence of traditional atherosclerotic risk factors.  The presence of atherosclerosis was not separately assessed. The presence of comorbid conditions was also assessed with the help of the Charlson comorbidity index. Additionally, Framingham coronary heart disease risk score was calculated; however, this was done only for women, because there were only a few male patients in the study cohort and male gender is an independent risk factor in this calculation.  

Results: As shown in Table 1, among the Framingham components, only hypertension was significantly more frequent in TA. When only females were analyzed, Framingham risk score was more likely to be higher only in TA. Framingham score of SLE pts was found to be similar to that of the healthy controls, despite an increased frequency of hypertension observed among SLE pts. Additionally, familial history of cardiovascular diseases and sudden death were significantly more common among the TA pts compared to the SLE pts and healthy controls. Pericardial/pleural and renal diseases were more frequently observed among the SLE pts, (Table 2). On the other hand, cardiovascular and chronic pulmonary diseases were more common in TA pts. The frequency of inflammatory upper/lower back pain and rheumatologic diseases were increased in both TA and SLE. However, inflammatory bowel diseases (IBD) were only observed among the TA pts.

Conclusion: Among the traditional atherosclerotic risk factors, only hypertension appears to be increased among the TA pts. The frequencies of IBD and inflammatory upper/lower back pain are substantially high and deserves further scrutiny. Moreover, the increased incidence of cardiovascular and rheumatologic diseases among the first-degree relatives of TA pts suggest that genetic mechanisms may play role in TA.

 

Table 1. The demographic features and cardiovascular risk factors among females 

 

Takayasu arteritis

(n = 77)

SLE

(n =77)

Healthy controls

(n =87)

p value

Age, mean ± SD

44.5 ±12.6

42.5 ±12.4

44.6 ± 11.4

0.454

Smoking (current and past), n (%)

24 (31)

33 (45)

37 (42)

0.160

Body mass index, mean ± SD

26 ± 5

26 ± 6

26 ± 5

0.987

Total cholesterol, mg/dl

192 ± 47

186  ± 44

193 ± 36

0.580

HDL cholesterol, mg/dl

56 ± 14

59.5 ± 19

57 ± 15

0.470

Hypertension, n (%)

44 (57)

24 (31)

19 (22)

<0.0011

Diabetes mellitus, n (%)

7 (9)

8 (10)

12 (14)

0.612

Familial history of cardiovascular diseases, n (%)

36 (47)

16 (21)

22 (25)

0.0012

Familial history of sudden death,

n (%)

20 (26) ††

11 (14)

10 (11.5)

0.0363

Framingham risk score, median [IQR]

4.1 [1.8-9.4]

3.3 [1.3-5.8]

3.2 [1.1-5.9]

0.056

1TA–Healthy controls and SLE-Healthy controls, p <0.05; 2TA –SLE and TA-Healthy controls, p <0.05; 3 TA-SLE and TA-Healthy controls, p <0.05

 

Table 2. Comorbid diseases and accompanying rheumatologic diseases across the groups

 

Takayasu arteritis

(n = 88)

SLE

(n =81)

Healthy controls

(n=111)

p value

Female/male

77/11

77/4

87/24

0.00411

Age, mean ± SD

44.0 ±12.3

42.3±12.3

44.3 ± 11.7

0.482

Disease duration, median (IQR)

7 [3-12.8]

7 [4-14]

–

0.213

Chronic pulmonary diseases, n (%)

11 (12.5)

2 (2.5)

5 (4.5)

0.01722

Cardiovascular diseases, n (%)

38 (43.2)

18 (22.2)

10 (9.0)

<0.00133

Renal diseases, n (%)

12 (13.6)

21 (25.9)

8 (7.2)

0.00144

Neurologic diseases, n (%)

14 (15.9)

9 (11.1)

4 (3.6)

0.01255

Thyroid diseases, n (%)

12 (13.6)

20 (24.7)

24 (21.6)

0.172

Antidepressant drug use, n (%)

26 (29.5)

30 (37.0)

19 (17.1)

0.00766

Rheumatologic diseases

19 (21.6)

16 (19.8)

1

0.768

        Crohn’s disease/Ulcerative colitis

9 (10.2)

0

0

 

        Ankylosing spondylitis

3

0

0

 

        Behçet’s syndrome

3

0

0

 

        Takayasu’s arteritis

0

1

0

 

        Rheumatoid arthritis

1

2

0

 

        Psoriasis

3

3

1

 

        Anti-phospholipid syndrome

0

7

0

 

        Sjögren’s syndrome

0

3

0

 

Inflammatory upper/lower back pain

21 (23.9)

23 (28.4)

6 (5.4)

<0.0017

Pericarditis/pleuritis

7 (8.0)

13 (16.0)

0

0.0018

Family history of rheumatologic diseases

26 (29.5)

23 (28.4)

5 (4.5)

<0.0019

1: TA-Healthy controls and SLE-Healthy controls, p<0.05; 2 TA-SLE and TA-Healthy controls, p<0.05; 3 TA-Healthy controls and SLE-Healthy controls, p<0.05; 4 SLE-TA and SLE-Healthy controls, p<0.05; 5 TA-Healthy controls and SLE-Healthy controls, p<0.05; 6 TA-Healthy controls and SLE-Healthy controls, p<0.05;7 TA-Healthy controls and SLE-Healthy controls, p<0.05; 8 TA-Healthy controls and SLE-Healthy controls, p<0.05; 9 TA-Healthy controls and SLE-Healthy controls, p<0.05

 

 


Disclosure: H. Masyan, None; S. N. Esatoglu, None; A. M. Celik, None; V. Hamuryudan, None; H. Yazici, None; E. Seyahi, None.

To cite this abstract in AMA style:

Masyan H, Esatoglu SN, Celik AM, Hamuryudan V, Yazici H, Seyahi E. Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-factors-and-comorbid-diseases-in-takayasus-arteritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-factors-and-comorbid-diseases-in-takayasus-arteritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology